Pay in 4 interest-free payments of $6.13 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
At a BMI of 30 or above, no comorbidity is required
The trial results demonstrated a favorable safety and tolerability profile consistent with GLP-1-based treatments and previously reported HRS9531 Phase 2 clinical data
CLA: A stimulant-free option that may help support body composition when paired with proper diet and exercise
Services are not intended to diagnose, treat, cure, or prevent disease
Wirth, F
Cardiovascular outcomes trials (SUSTAIN-6, SELECT) demonstrate that long-term use reduces heart attack and stroke risk in people with obesity and existing heart disease
US$ 22.21
US$ 23.17
US$ 28.89
US$ 23.37
US$ 20.45
